» Articles » PMID: 9620903

Circulating Immunoreactive Interleukin-6 in Cystic Fibrosis

Overview
Specialty Critical Care
Date 1998 Jun 25
PMID 9620903
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

We measured circulating and sputum-sol concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), neutrophil elastase-alpha1-antiproteinase complex (NEAPC), and C-reactive protein (CRP) in an exacerbation, after antibiotic treatment, and in clinically stable patients with cystic fibrosis and chronic pulmonary infection with Pseudomonas aeruginosa. The aim was to determine the compartmental patterns of a proinflammatory and anti-inflammatory cytokine compared with other markers of inflammatory activity in cystic fibrosis. IL-6, NEAPC, CRP, and absolute neutrophil count were reduced after antibiotic treatment, p < 0.01. IL-6 and CRP concentrations were greater, p = 0.007, and p = 0.01, respectively, in a stable group of patients compared with those at the end of an exacerbation. IL-6 and CRP concentrations were related (r = 0.836, p < 0.0001), and both were greater than in matched control subjects (p < 0.001) at all times studied. Sputum-sol concentrations of IL-6 after treatment were positively related to FEV1 and FVC and inversely related to concentrations of neutrophil elastase. The separation between patients and healthy subjects, and the reduction of IL-6 after antibiotic treatment indicates it could be used as a marker of inflammation, but its relationship to other markers depends on the compartment in which it is measured.

Citing Articles

A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model.

Carbone A, Vitullo P, Di Gioia S, Castellani S, Conese M Curr Issues Mol Biol. 2024; 46(9):10396-10410.

PMID: 39329970 PMC: 11430433. DOI: 10.3390/cimb46090618.


APPLICATION OF QUANTILE DISCRETIZATION AND BAYESIAN NETWORK ANALYSIS TO PUBLICLY AVAILABLE CYSTIC FIBROSIS DATA SETS.

Fukutani K, Hampton T, Bobak C, MacKenzie T, Stanton B Pac Symp Biocomput. 2023; 29:534-548.

PMID: 38160305 PMC: 10783867.


ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor-ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis-an observational study.

Arooj P, Morrissy D, McCarthy Y, Vagg T, McCarthy M, Fleming C BMJ Open Respir Res. 2023; 10(1).

PMID: 37130650 PMC: 10163494. DOI: 10.1136/bmjresp-2022-001590.


Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.

Westholter D, Raspe J, Uebner H, Pipping J, Schmitz M, Strassburg S Front Immunol. 2023; 14:1107437.

PMID: 36875141 PMC: 9978140. DOI: 10.3389/fimmu.2023.1107437.


Diagnosis and Management of Cystic Fibrosis Exacerbations.

Milinic T, McElvaney O, Goss C Semin Respir Crit Care Med. 2023; 44(2):225-241.

PMID: 36746183 PMC: 10131792. DOI: 10.1055/s-0042-1760250.